Fosun Pharma Subsidiary Obtains NMPA Green Light for Venlafaxine Sustained-Release Tablets

Bulletin Express

May 08

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval for Venlafaxine Hydrochloride Sustained-release Tablets (75 mg). The product is indicated for the treatment of depression—including depression with anxiety—and generalized anxiety disorder.

Classified as a Class 3 chemical medicine, the tablet is the Group’s proprietary development. Cumulative R&D investment reached approximately RMB7.68 million as of April 2026.

Market data from IQVIA CHPA show that domestic sales of all Venlafaxine Hydrochloride formulations in mainland China totaled about RMB584 million in 2025, underscoring the product’s commercial potential. Management stated that the new approval expands the Group’s central-nervous-system portfolio, while cautioning that actual sales will depend on market demand, competitive dynamics, and distribution capabilities.

The approval is formalized under drug registration number Guo Yao Zhun Zi H202641902. The board issued the announcement on 8 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1188124715"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188124715\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188124715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188124715","market":"hk","top_or_hot":-1,"title":"Fosun Pharma Subsidiary Obtains NMPA Green Light for Venlafaxine Sustained-Release Tablets","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval for Venlafaxine Hydrochloride Sustained-release Tablets (75 mg). The product is indicated for the treatment of depression—including depression with anxiety—and generalized anxiety disorder.</p>\n<p>Classified as a Class 3 chemical medicine, the tablet is the Group’s proprietary development. Cumulative R&D investment reached approximately RMB7.68 million as of April 2026.</p>\n<p>Market data from IQVIA CHPA show that domestic sales of all Venlafaxine Hydrochloride formulations in mainland China totaled about RMB584 million in 2025, underscoring the product’s commercial potential. Management stated that the new approval expands the Group’s central-nervous-system portfolio, while cautioning that actual sales will depend on market demand, competitive dynamics, and distribution capabilities.</p>\n<p>The approval is formalized under drug registration number Guo Yao Zhun Zi H202641902. The board issued the announcement on 8 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Subsidiary Obtains NMPA Green Light for Venlafaxine Sustained-Release Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Subsidiary Obtains NMPA Green Light for Venlafaxine Sustained-Release Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-08 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval for Venlafaxine Hydrochloride Sustained-release Tablets (75 mg). The product is indicated for the treatment of depression—including depression with anxiety—and generalized anxiety disorder.</p>\n<p>Classified as a Class 3 chemical medicine, the tablet is the Group’s proprietary development. Cumulative R&D investment reached approximately RMB7.68 million as of April 2026.</p>\n<p>Market data from IQVIA CHPA show that domestic sales of all Venlafaxine Hydrochloride formulations in mainland China totaled about RMB584 million in 2025, underscoring the product’s commercial potential. Management stated that the new approval expands the Group’s central-nervous-system portfolio, while cautioning that actual sales will depend on market demand, competitive dynamics, and distribution capabilities.</p>\n<p>The approval is formalized under drug registration number Guo Yao Zhun Zi H202641902. The board issued the announcement on 8 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1188124715","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188124715","pubTimestamp":1778232272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药子公司文拉法辛缓释片获NMPA绿灯","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Fosun Pharma (Xuzhou) Co., Ltd., has received National Medical Products Administration approval for Venlafaxine Hydrochloride Sustained-release Tablets (75 mg). The product is indicated for the treatment of depression—including depression with anxiety—and generalized anxiety disorder.\nClassified as a Class 3 chemical medicine, the tablet is the Group’s proprietary development. Cumulative R&D investment reached approximately RMB7.68 million as of April 2026.\nMarket data from IQVIA CHPA show that domestic sales of all Venlafaxine Hydrochloride formulations in mainland China totaled about RMB584 million in 2025, underscoring the product’s commercial potential. Management stated that the new approval expands the Group’s central-nervous-system portfolio, while cautioning that actual sales will depend on market demand, competitive dynamics, and distribution capabilities.\nThe approval is formalized under drug registration number Guo Yao Zhun Zi H202641902. The board issued the announcement on 8 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}